Preservative-free treatment can help selected patients, but symptom relief, pressure control and long-term surgical benefit are different outcomes.
Terminology and draft status
Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.
01Identify exposure before assigning blame
Benzalkonium chloride (BAK) is a quaternary ammonium preservative used in many multidose drops. Its antimicrobial detergent action can also affect epithelial membranes and the tear film; toxicity depends on concentration, frequency, duration, formulation and the individual surface. 1
Preservatives protect against contamination, but not every multidose system needs a chemical preservative: validated containers can maintain microbiological safety. The export also names cetrimide (its spelling Zitrimit remains unresolved), thiomersal, parabens, chlorhexidine and polymyxin B; their roles differ, and chlorhexidine or polymyxin used as active anti-infectives must not be treated as interchangeable excipients. 1
02Separate laboratory toxicity from clinical outcomes
The original threshold 0.005%, the range 0.005–0.02%, damage above 0.05% and animal exposure up to 1.0% are retained in the table as exposure examples. Without the exact model and exposure time they do not establish a universal human toxicity threshold or predict the effect of one prescribed drop. 1
The identified 2020 systematic review included 16 studies; 13 trials with 4201 participants contributed to IOP analysis over 15 days to 6 months. Pressure differences were small, while safety reporting was heterogeneous and bias often high or unclear. This does not prove identical anterior-chamber penetration, equal long-term safety or a universal advantage for every preservative-free preparation. 2
| Original BAK exposure | Interpretation |
|---|---|
| 0.005–0.02% | Common formulation range; tear-film/epithelial effects depend on model and exposure |
| >0.05% | Original necrosis/cytotoxicity claim; no universal clinical threshold established here |
| Up to 1.0% | Original animal anterior-segment/endothelial destruction; not routine human dose |
03Examine tear film, epithelium and nerves
BAK exposure can disturb the lipid layer and epithelial integrity, with shorter tear break-up time (BUT), staining, goblet-cell loss and inflammatory changes. Schirmer testing estimates aqueous tear production; it is not a direct measurement of tear turnover. Meibomian gland dysfunction (MGD; original MDD) and the active drug may contribute independently. 1
Confocal nerve changes and reduced corneal sensitivity are possible findings, not proof that every symptom is neurotoxicity. The original cyclosporin A 0.05% twice daily for 6 months and nerve-regeneration claim lacks a verified study here; it is not a guaranteed restorative treatment or a general prescription. 1
MMP9 reflects inflammation but is not specific for preservative toxicity. The original 50% versus 17% positive-test comparison lacks a verified denominator and design. Hyperaemia alone does not prove inflammation: netarsudil-associated vasodilatation, allergy, infection and surface injury require different management; the export spelling Netasudil/Rocklander is unresolved product terminology. 1
04Interpret scarring and surgery evidence cautiously
Chronic conjunctival inflammation can involve lymphocytes, dendritic cells and fibroblasts and may contribute to scarring, including drug-associated pseudopemphigoid. Progressive cicatrisation needs assessment for other causes such as mucous-membrane pemphigoid; the appearance alone does not establish a drug cause. 1
The export cites Broadway and a primary filtration success of 90% without the exact study or endpoint. Conjunctival cell-profile associations are not randomised proof that BAK alone causes surgical failure; disease severity, treatment duration, multiple drugs and operative technique can confound comparisons. Preserve this concern when planning surgery, without promising a specific success gain after switching drops. 1
Experimental oxidative stress and apoptosis in trabecular cells motivate research. The original term inflammatory trabeculopathy does not establish that routine preserved treatment destroys pressure regulation in every patient; effective IOP lowering remains essential to protect vision. 1
05Ask how treatment is actually used
Adherence means taking treatment as agreed; persistence means continuing it over time. Original estimates of 70% with prostaglandins, adherence 89% versus 63% with surface symptoms and 33–39% persistence at 1 year have unverified populations and definitions. Symptoms matter, but affordability, dexterity, cognition, schedule and access also influence use. 1
Ask about burning, foreign-body sensation, fluctuating vision and self-discontinuation without blaming the patient. Observe instillation, review the number of drops and consider simpler or fixed-combination regimens if clinically appropriate, while checking pressure and tolerability. 1
06Choose a surface plan without losing pressure control
Assess symptoms, BUT, corneal/conjunctival staining, lids and meibomian function. A BUT <10 seconds is an original teaching threshold, not a diagnosis by itself; MMP9 can be supplementary and is not mandatory for every patient. The cited 2024 Delphi consensus is unidentified and cannot be called a verified guideline. 1
Review a possible switch to a suitable preservative-free pressure drug and preservative-free lubricants, with an agreed IOP check. Treat lid disease with appropriate warming and hygiene; doxycycline requires selected indications and contraindication review. A change is individual, not an automatic immediate switch for every red eye. 1
Selected anti-inflammatory treatment may include short monitored topical steroids or cyclosporin after excluding infection; steroids can raise IOP and require caution in glaucoma. SLT or surgery may reduce drop burden in eligible eyes, but neither is indicated solely by an unconfirmed toxicity label. Preservative-free treatment is a useful option, not a universally established gold standard or a reason to abandon effective therapy. 1
| Topic | Mechanism hypothesis | Finding | Management and limit |
|---|---|---|---|
| BAK surface effect | Detergent/membrane disturbance | Short BUT and staining | Review exposure and suitable PF option; preserve IOP control |
| Epithelial cells | Apoptosis/goblet-cell loss | Dryness and mucin disturbance | PF lubricants and cause-specific care, not proof from symptoms alone |
| Inflammation | Cytokines/MMP9 | Follicular or inflammatory surface signs | Exclude infection/allergy; selected monitored anti-inflammatory care |
| Nerve changes | Possible subepithelial injury | Reduced sensitivity | Evaluate other causes; no guaranteed CsA nerve restoration |
| Fibrosis | Inflammatory/fibroblast response | Scarring and surgical concern | Plan surface optimisation; no proven universal surgical success gain |
What are the main learning points?
Preservative-free treatment can help selected patients, but symptom relief, pressure control and long-term surgical benefit are different outcomes.
When is assessment urgent?
Sudden visual loss, severe pain, corneal ulceration or marked pressure elevation requires urgent assessment. Do not stop pressure-lowering treatment without an agreed alternative.
References and access status
- 1Immutable original export; preservative lecture; named quotations/appointments unverified
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2Hedengran et al. 2020 systematic review; PMID 32051133
Selected indexed abstract methods/results read 16 November 2026; 16 studies, IOP analysis 13/4201, short heterogeneous follow-up and high/unclear bias. Full report/supplement unread; no penetration equivalence established.
For patients
Burning or redness during treatment deserves review. The active drug, preservative, dry eye, allergy and lid disease can all contribute.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Sudden visual loss, severe pain, corneal ulceration or marked pressure elevation requires urgent assessment. Do not stop pressure-lowering treatment without an agreed alternative.
Sudden visual loss, severe pain, corneal ulceration or marked pressure elevation requires urgent assessment. Do not stop pressure-lowering treatment without an agreed alternative.